Yasser Jamil

Apr 5, 2024 | jacc.org | Rohin K Reddy |James Howard |Yasser Jamil |Mahesh V. Madhavan

References1. "2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)". Eur Heart J . 2023;44:38: 3720-3826. 2. "2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol . 2022;79:197-215. 3.

Apr 3, 2024 | mdpi.com | Yasser Jamil |Yousif Ahmad |Theresa Coles |Hayden Barry Bosworth

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Mar 28, 2024 | jamanetwork.com | Jiun-Ruey Hu |Yasser Jamil |Michelle D. Kelsey |W. Schuyler Jones

Key PointsQuestion  What is the optimal duration of dual antiplatelet therapy (DAPT) in terms of net adverse clinical events, major cardiovascular events, and bleeding for older adults after percutaneous coronary intervention (PCI)? Findings  In this systematic review and network meta-analysis of 14 randomized clinical trials, no differences in net adverse clinical events and major adverse cardiovascular events were seen for 1, 3, 6, and 12 months of DAPT.